Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVSQIV in healthy adults
NCT05252338Phase 1Completed
- Sponsor
- CureVac
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of CVSQIV in influenza (2 arms), sponsored by CureVac. Primary endpoints: Frequencies of Grade 3 Adverse Reactions and any Serious Adverse Reaction within 20 hours, Frequencies of Grade 3 Adverse Reactions and any Serious Adverse Reaction within 60 hours and 4 more. Started Feb 2022; status: completed.
02
Drugs
CVSQIV
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05252338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05252338.